Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The HIV Prevention Trials Network 052 study (HPTN 052) was a clinical trial designed to determine whether early treatment for HIV infection prevented transmission of the virus in couples where one partner was infected with HIV and the other was not, referred to as HIV serodiscordant or serodifferent couples. The study enrolled 1,763 couples at 13 sites in 9 countries in Asia, Africa, and the Americas. HPTN 052 demonstrated a minimum of 96% reduction of HIV in heterosexual couples ascribed to antiretroviral treatment; early treatment of HIV significantly reduced other infections in the HIV-infected subjects. This study, in conjunction with similar research, led to significant changes in international HIV treatment guidelines and the concept of treatment as prevention (TasP). This article provides the scientific background and history of how HPTN 052 came into being, the challenges it faced, and the ultimate impact it had on the fields of HIV treatment and prevention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1146/annurev-med-110918-034551 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between substance use and PrEP adherence among adolescent girls and young women enrolled in an HIV prevention study in Southern Africa.
PLOS Glob Public Health
June 2025
Clinical Trials Research Centre, University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe.
Adolescent girls and young women (AGYW) in sub-Saharan Africa are at substantial risk of HIV acquisition and could benefit from oral pre-exposure prophylaxis (PrEP) for HIV prevention. Substance use may result in poor adherence, diminishing PrEP effectiveness. The effects of substance use on PrEP adherence in AGYW within the African context have not been extensively studied.
View Article and Find Full Text PDFPregnancy rates and clinical outcomes among women living with HIV enrolled in HPTN 052.
AIDS Care
June 2023
David Geffen UCLA School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
HPTN 052 was a multi-country clinical trial of cART for preventing heterosexual HIV-1 transmission. The study allowed participation of pregnant women and provided access to cART and contraceptives. We explored associations between pregnancy and clinical measures of HIV disease stage and progression.
View Article and Find Full Text PDFSexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052.
Int J STD AIDS
November 2021
Department of Medicine, 6797University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sexually transmitted infections (STIs) remain a public health concern because of their interaction(s) with HIV. In the HPTN 052 study, STIs were evaluated in both HIV-positive index cases and their HIV-negative partners at enrollment and at yearly follow-up visits. Our definition for STI was based on any infection with , syphilis, or We used log-binomial regression models to identify factors associated with prevalent STIs.
View Article and Find Full Text PDFEvaluation of Phylogenetic Methods for Inferring the Direction of Human Immunodeficiency Virus (HIV) Transmission: HIV Prevention Trials Network (HPTN) 052.
Clin Infect Dis
January 2021
Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background: Phylogenetic analysis can be used to assess human immunodeficiency virus (HIV) transmission in populations. We inferred the direction of HIV transmission using whole-genome HIV sequences from couples with known linked infection and known transmission direction.
Methods: Complete next-generation sequencing (NGS) data were obtained for 105 unique index-partner sample pairs from 32 couples enrolled in the HIV Prevention Trials Network (HPTN) 052 study (up to 2 samples/person).
Prevention of HIV Transmission and the HPTN 052 Study.
Annu Rev Med
January 2020
Science Facilitation Department, HIV Prevention Trials Network (HPTN) Leadership and Operations Center, FHI 360, Durham, North Carolina 27701, USA; email:
The HIV Prevention Trials Network 052 study (HPTN 052) was a clinical trial designed to determine whether early treatment for HIV infection prevented transmission of the virus in couples where one partner was infected with HIV and the other was not, referred to as HIV serodiscordant or serodifferent couples. The study enrolled 1,763 couples at 13 sites in 9 countries in Asia, Africa, and the Americas. HPTN 052 demonstrated a minimum of 96% reduction of HIV in heterosexual couples ascribed to antiretroviral treatment; early treatment of HIV significantly reduced other infections in the HIV-infected subjects.
View Article and Find Full Text PDF